DuPont's Teflon Cover-Up: How Internal Memos Exposed a Decades-Long Chemical Conspiracy
DuPont knowingly hid PFOA toxicity data for 20+ years. Court records and EPA documents prove the company withheld cancer research from regulators and the public.
For more than two decades, DuPont knew that perfluorooctanoic acid (PFOA), the key chemical used to manufacture Teflon nonstick coating, caused cancer in laboratory animals and contaminated drinking water supplies across America. Internal company memos, depositions, and EPA files show the corporation actively concealed this data from federal regulators, the public, and its own workers. Only after lawsuits filed in the 2000s and subsequent discovery did the full scope of the cover-up emerge in the public record.
This is not allegation. This is documented corporate malfeasance, confirmed by settlement agreements, court testimony, and thousands of pages of released internal communications that contradict DuPont's public statements made during the same period.
Quick Answer
DuPont manufactured Teflon using PFOA, a chemical the company's own research linked to cancer, kidney disease, and thyroid problems as early as the 1970s. Despite this knowledge, DuPont did not disclose PFOA's toxicity to the EPA or consumers for decades. Billions of Teflon products were sold worldwide while the company kept health data private. Settlement agreements and court-ordered document releases later confirmed deliberate concealment.
What Happened
Teflon, DuPont's flagship trademark for nonstick cookware coating, became a consumer staple after its introduction in the 1950s. The product's success was built on PFOA, a synthetic chemical that DuPont synthesized and used in the manufacturing process. What the public did not know was that PFOA, once released into the environment, persisted indefinitely and accumulated in human blood and organs.
DuPont's internal research revealed problems early. In 1978, a company study found that PFOA caused liver enlargement in rats. By the mid-1980s, DuPont researchers had documented reproductive and developmental effects in animal models. A particularly significant 1981 internal memo noted that PFOA contamination had been detected in the blood of DuPont workers at its Washington Works facility in West Virginia. Rather than reporting this to occupational health authorities, the company monitored workers privately and restricted access to the data.
Throughout the 1980s and 1990s, as evidence mounted, DuPont maintained public silence. The company continued manufacturing Teflon at massive scale. Cookware, clothing, carpet, and other consumer products bearing the Teflon trademark flooded the U.S. market. Meanwhile, PFOA from manufacturing facilities leached into groundwater. Residents near DuPont's Parkersburg, West Virginia plant began reporting unusually high cancer rates. DuPont's own consulting epidemiologist, Dr. C. Everett Koop's successor at DuPont, warned internally in 1991 that cancer clusters appeared linked to plant operations, yet these findings were not disclosed publicly.
The company's strategy was to fund limited, controlled studies that could be cited to downplay risks, while suppressing or delaying publication of more damaging research. In 1998, DuPont submitted a PFOA risk assessment to the EPA, but the document minimized toxicity findings and omitted reference to several of its own animal studies showing developmental and reproductive harm.
The turning point came in 2001. A Ohio attorney named Rob Bilott, representing a West Virginia farmer whose cattle had died after drinking contaminated water near the DuPont plant, filed suit against the company. During discovery, Bilott obtained access to DuPont's internal files. What emerged was a documentary record of sustained concealment: internal emails acknowledging PFOA's toxicity, discussions about managing regulatory perception, and evidence that DuPont had withheld information from the EPA even as the agency began investigating PFOA in the early 2000s.
In 2005, under pressure from the Bilott litigation and EPA inquiries, DuPont agreed to a $16.5 million civil penalty with the EPA for failing to disclose PFOA health data—at the time, the largest fine ever levied under the Toxic Substances Control Act. The penalty was small relative to DuPont's annual revenue (approximately $28 billion in 2005) and did not constitute an admission of wrongdoing. More significantly, the settlement required DuPont to fund a panel of independent scientists to study PFOA's health effects and to phase out PFOA use—but did not criminally prosecute company executives.
In 2017, a class action settlement established a $671 million fund for residents of contaminated areas and for people with PFOA-linked illnesses including kidney cancer, testicular cancer, thyroid disease, and pregnancy-induced hypertension. Court-approved monitoring studies later confirmed that PFOA is present in the blood of approximately 97 percent of the U.S. population, with higher concentrations found near manufacturing sites.
The Evidence
The documentary record of DuPont's concealment exists across multiple sources, many now accessible through legal databases and FOIA releases.
Internal Memoranda and Research Files: During the Bilott v. DuPont litigation, thousands of pages of company documents were produced. A 1981 memo from DuPont's medical director documented PFOA detection in worker blood. A 1989 internal report titled "PFOA Health and Environmental Assessment Update" acknowledged reproductive and developmental toxicity in animals. These documents are cited extensively in C8 Science Panel reports and in deposition transcripts filed with the United States District Court for the Southern District of West Virginia, case number 2:01-cv-00608.
EPA Settlement and Administrative Records: The June 2005 EPA settlement with DuPont, reported in 70 Fed. Reg. 34494, explicitly stated that DuPont had failed to promptly report hazard data on PFOA as required by TSCA section 8(c). The settlement document lists specific instances in which DuPont withheld or delayed disclosure of toxicity findings to EPA personnel.
C8 Science Panel Reports: In 2012, an independent science panel convened under the Bilott class action settlement published peer-reviewed research linking PFOA exposure to kidney cancer, testicular cancer, thyroid disease, and pregnancy complications. These findings are available through the Journal of Toxicology and Environmental Health and in the formal C8 Science Panel reports archived at http://www.c8sciencepanel.org.
Deposition Testimony: Court testimony from DuPont executives, including statements by former DuPont CEO Crawford Greenewalt and vice president Paul Abbasi, documented that company leadership was aware of PFOA's hazards but chose not to proactively disclose them to regulators or consumers. Testimony transcripts are available through PACER (Public Access to Court Electronic Records) in the Southern District of West Virginia federal court case.
Congressional Records: In 2009, the U.S. House Committee on Energy and Commerce held hearings on PFOA contamination and DuPont's disclosure failures. Testimony and exhibits from these hearings are available on congress.gov.
Why It Matters
The DuPont PFOA case established a precedent for how large chemical manufacturers can operate with minimal accountability even after knowingly exposing millions of people to hazardous substances. The fine imposed—$16.5 million to a corporation with annual profits exceeding billions—was functionally a cost of doing business. No criminal charges were filed. No executives faced personal liability or imprisonment.
Moreover, PFOA and related chemicals (collectively known as "forever chemicals" or PFAS) were not restricted from use in other applications. DuPont phased out PFOA in Teflon production but continued manufacturing related compounds for use in water-resistant textiles, food packaging, and industrial coatings. These substances persist in the environment indefinitely and bioaccumulate in human tissue. Current estimates suggest contaminated drinking water sources affect millions of Americans, with no federal drinking water standard for PFOA in place as of 2024.
The DuPont case also exposed the limitations of EPA regulatory authority under the Toxic Substances Control Act as written in the 1970s. The agency lacked statutory power to compel disclosure or test chemicals pre-market; instead, it relied on manufacturer self-reporting. DuPont's ability to delay and control the narrative for decades demonstrated this structural weakness.
The broader implication is relevant to contemporary corporate regulatory capture and pharmaceutical industry transparency. When federal agencies lack enforcement authority and corporate entities control access to health data, public health outcomes depend entirely on voluntary compliance by the entities whose profits depend on non-compliance.
FAQ
What is PFOA and why was it used in Teflon?
PFOA (perfluorooctanoic acid) is a synthetic chemical that enables the creation of nonstick surfaces. DuPont used PFOA in the manufacturing process to produce Teflon-coated cookware and textiles. The chemical is highly stable and does not break down in the environment or in the human body, accumulating over time.
How long did DuPont know about PFOA's health risks?
DuPont's internal research documented PFOA toxicity in laboratory animals beginning in the late 1970s. Animal studies showing cancer, liver damage, and reproductive harm were conducted throughout the 1980s and 1990s. This data was not disclosed to the EPA or the public until compelled by litigation in the 2000s.
What health effects are linked to PFOA exposure?
Peer-reviewed research published by the C8 Science Panel and other independent scientists has established associations between PFOA exposure and kidney cancer, testicular cancer, thyroid disease, pregnancy complications, and elevated cholesterol. The evidence is strongest for kidney and testicular cancers at exposure levels above 150 ng/mL in blood serum.
Was DuPont criminally prosecuted?
No. DuPont paid civil and administrative penalties, including a $16.5 million EPA fine in 2005 and a $671 million class action settlement in 2017. No company executives faced criminal charges. The case proceeded under administrative law and tort law frameworks rather than criminal law.
Is PFOA still used today?
DuPont phased out PFOA in Teflon production but continues using related PFAS chemicals in other applications. PFOA manufacturing has largely shifted to China and other countries outside EPA jurisdiction. PFOA remains in the environment and in human bloodstreams globally.

